MX2021001807A - Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma. - Google Patents

Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma.

Info

Publication number
MX2021001807A
MX2021001807A MX2021001807A MX2021001807A MX2021001807A MX 2021001807 A MX2021001807 A MX 2021001807A MX 2021001807 A MX2021001807 A MX 2021001807A MX 2021001807 A MX2021001807 A MX 2021001807A MX 2021001807 A MX2021001807 A MX 2021001807A
Authority
MX
Mexico
Prior art keywords
inhibitor
protein kinase
histone deacetylase
combination
kinase inhibitor
Prior art date
Application number
MX2021001807A
Other languages
English (en)
Inventor
Lijun Xin
Desi Pan
Song Shan
Xianping Lu
Zhiqiang Ning
You Zhou
Yanan Wang
Shigang Wang
Original Assignee
Shenzhen Chipscreen Biosciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Chipscreen Biosciences Co Ltd filed Critical Shenzhen Chipscreen Biosciences Co Ltd
Publication of MX2021001807A publication Critical patent/MX2021001807A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Uso de una combinación de un inhibidor de histona desacetilasa y un inhibidor de proteína cinasa en la preparación de un medicamento para el tratamiento o prevención de tumores, una composición farmacéutica que comprende un inhibidor de histona desacetilasa y un inhibidor de proteína cinasa como principios activos, y un método para tratar o prevenir cánceres mediante la combinación de un inhibidor de histona desacetilasa y un inhibidor de proteína cinasa.
MX2021001807A 2018-08-17 2019-08-12 Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma. MX2021001807A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810943005.6A CN110833544B (zh) 2018-08-17 2018-08-17 组蛋白去乙酰化酶抑制剂与蛋白激酶抑制剂之组合及其制药用途
PCT/CN2019/100175 WO2020034916A1 (zh) 2018-08-17 2019-08-12 组蛋白去乙酰化酶抑制剂与蛋白激酶抑制剂之组合及其制药用途

Publications (1)

Publication Number Publication Date
MX2021001807A true MX2021001807A (es) 2021-04-19

Family

ID=69524705

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001807A MX2021001807A (es) 2018-08-17 2019-08-12 Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma.

Country Status (14)

Country Link
US (1) US20210315881A1 (es)
EP (1) EP3838273A4 (es)
JP (1) JP7186858B2 (es)
KR (1) KR102590221B1 (es)
CN (2) CN114681455A (es)
AU (1) AU2019320922B9 (es)
BR (1) BR112021002754A2 (es)
CA (1) CA3108811C (es)
MX (1) MX2021001807A (es)
RU (1) RU2770754C1 (es)
TW (1) TWI721526B (es)
UA (1) UA126840C2 (es)
WO (1) WO2020034916A1 (es)
ZA (1) ZA202101307B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112294810B (zh) * 2019-07-29 2024-03-01 深圳微芯生物科技股份有限公司 含有西达本胺和表面活性剂的药物组合物
TWI741731B (zh) * 2019-08-15 2021-10-01 大陸商深圳微芯生物科技股份有限公司 一種含西達本胺的抗腫瘤藥物組合物及其應用
CN113440615A (zh) * 2020-03-24 2021-09-28 深圳微芯生物科技股份有限公司 包含蛋白激酶抑制剂和化疗药物的药物组合物及其用途
WO2022007745A1 (zh) * 2020-07-08 2022-01-13 深圳微芯生物科技股份有限公司 西奥罗尼及其联合用药治疗非霍奇金淋巴瘤的用途
WO2022022541A1 (zh) * 2020-07-29 2022-02-03 深圳微芯生物科技股份有限公司 Rbm10基因的用途
US20230321074A1 (en) * 2020-09-09 2023-10-12 Shenzhen Chipscreen Biosciences, Co., Ltd. Use of chiauranib in combination with immune checkpoint inhibitor in antitumor therapy
CN117597124A (zh) * 2021-07-08 2024-02-23 深圳微芯生物科技股份有限公司 西奥罗尼及其联合用药治疗乳腺癌的用途
WO2023160647A1 (zh) * 2022-02-24 2023-08-31 康方药业有限公司 包含抗ctla4-抗pd-1双特异性抗体和西奥罗尼的药物组合
CN116889565A (zh) * 2022-04-07 2023-10-17 深圳微芯生物科技股份有限公司 西奥罗尼在抗胰腺癌中的用途
CN115177620A (zh) * 2022-07-18 2022-10-14 厦门大学附属第一医院 西奥罗尼或其药学上可接受的盐在制备预防或治疗滤泡淋巴瘤的药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1545536A4 (en) * 2002-09-19 2009-11-11 Univ South Florida METHOD OF TREATING LEUKEMIA USING A COMBINATION OF HYDROMAXIC ACID SUBEROYLANILIDE AND IMATINIBE MESYLATE
AU2008335469A1 (en) * 2007-12-13 2009-06-18 Novartis Ag Combinations of therapeutic agents for treating cancer
CN101837129B (zh) * 2009-03-19 2012-12-12 鼎泓国际投资（香港）有限公司 含cMet抑制剂、HDAC抑制剂与EGFR酪氨酸激酶抑制剂的药物组合物及其应用
US8211901B2 (en) * 2009-05-22 2012-07-03 Shenzhen Chipscreen Biosciences Ltd. Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
CN101906076B (zh) * 2009-06-04 2013-03-13 深圳微芯生物科技有限责任公司 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用
CN102441167B (zh) * 2010-10-12 2014-05-07 鼎泓国际投资（香港）有限公司 含有芹菜素及芹菜素类衍生物和组蛋白去乙酰化酶抑制剂的药物组合物及其应用
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
CN103432077A (zh) * 2013-08-21 2013-12-11 北京淦航医药科技有限公司 西达苯胺固体分散制剂
WO2015054197A1 (en) * 2013-10-10 2015-04-16 Acetylon Pharmaceuticals, Inc. Hdac inhibitors, alone or in combination with btk inhibitors, for treating non-hodgkin's lymphoma
CN104771363A (zh) * 2014-01-14 2015-07-15 深圳微芯生物科技有限责任公司 一种西达本胺固体分散体及其制备方法与应用
AU2017298473A1 (en) * 2016-07-20 2019-01-24 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and compositions and uses thereof

Also Published As

Publication number Publication date
RU2770754C1 (ru) 2022-04-21
JP2021534142A (ja) 2021-12-09
TWI721526B (zh) 2021-03-11
BR112021002754A2 (pt) 2021-05-11
CN110833544A (zh) 2020-02-25
CN110833544B (zh) 2022-08-09
ZA202101307B (en) 2022-06-29
CA3108811C (en) 2023-09-05
US20210315881A1 (en) 2021-10-14
WO2020034916A1 (zh) 2020-02-20
AU2019320922B2 (en) 2022-11-17
JP7186858B2 (ja) 2022-12-09
CA3108811A1 (en) 2020-02-20
KR20210046700A (ko) 2021-04-28
AU2019320922A1 (en) 2021-03-18
CN114681455A (zh) 2022-07-01
AU2019320922B9 (en) 2023-03-23
UA126840C2 (uk) 2023-02-08
TW202033195A (zh) 2020-09-16
KR102590221B1 (ko) 2023-10-19
EP3838273A4 (en) 2022-05-04
EP3838273A1 (en) 2021-06-23

Similar Documents

Publication Publication Date Title
MX2021001807A (es) Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma.
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
PH12021550992A1 (en) Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors
EP4241850A3 (en) Mdm2 inhibitors and combinations thereof
SG10201902664RA (en) Combination therapy for treating cancer
MX2019012884A (es) Terapia de combinacion.
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
MX2022011372A (es) Composiciones de zinc-y-pga y metodos para tratar el cancer.
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
WO2018027084A3 (en) Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer
PH12020500099A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor
MX2021007453A (es) Administracion perineural de resiniferatoxina para el tratamiento del dolor maladaptativo.
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
EP3964520A4 (en) NEW OLIGOPEPTIDE AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER USING IT AS AN ACTIVE SUBSTANCE
PH12019501642A1 (en) Novel compounds and their use in the treatment of schistosomiasis
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2020002336A (es) Composicion lipolitica que contiene derivados de fosfocolina.
MX2022006179A (es) Derivados macrociclicos de indol como inhibidores de mcl-1.
MX2022006180A (es) Derivados macrociclicos de sulfonilo como inhibidores de mcl-1.
PH12021550660A1 (en) Pharmaceutical composition comprising histone deacetylase inhibitor and methotrexate
PH12020500510A1 (en) Prophylactic and/or therapeutic agent for diseases involving ido expression
MX2021016093A (es) Composicion farmaceutica para tratar un tumor.